Share
 
Title
Code
Session Type
Channel
Date Time
Co-Chairs:

OA12.01 Fine-tuning of in vitro transcribed mRNA for optimising a vaccine platform against HIV-1
Sergio LINARES FERNANDEZ, CNRS and University Claude Bernard Lyon 1, France
Abstract

OA12.02 Comparison of co-immunization of DNA and protein in the same anatomical sites and in contralateral sites to identify mechanisms of protective immune response
Barbara FELBER, National Cancer Institute at Frederick, United States
Abstract
Slides
OA12.03 Tetravalent immunogen assembled from conserved regions of HIV-1 and delivered as mRNA demonstrates potent preclinical T cell immunogenicity and breadth
Nathifa MOYO, United Kingdom
Abstract

OA12.04LB A VSV-based HIV-1 vaccine provides protection in macaques against low dose cross-clade SHIVenv_SF162_P3 challenge
Eric ARTS, Western University, Canada
Abstract
Slides

OA12.05 Improved in vitro expression and in vivo immunogenicity of a candidate MVA-vectored HIV-1 vaccine compared to SAAVI MVA-C
Nicola DOUGLASS, University of Cape Town, South Africa
Abstract

OA12.06 Live Q&A